360 filings
Page 5 of 18
8-K
vhj jyl5fip73ro
7 Aug 18
Dynavax Reports Second Quarter 2018 Financial Results
12:00am
8-K
6tlbrpothoaldol
5 Jun 18
Other Events
12:00am
8-K
6uqip6vfhhmj
1 Jun 18
Departure of Directors or Certain Officers
4:50pm
8-K
emgynhavy62vdzurx5o7
9 May 18
Dynavax Reports First Quarter 2018 Financial Results
4:10pm
8-K
uqgcf1gfxc f2
26 Apr 18
Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report
4:10pm
8-K
tcebng82c44r
18 Apr 18
Other Events
12:00am
8-K
ak5tu 4obx1
8 Mar 18
Dynavax Reports Fourth Quarter and Year End 2017 Financial Results
12:00am
8-K
z2vf 43hp88j4r4ibs3f
2 Mar 18
Departure of Directors or Certain Officers
12:00am
8-K
69y13mou
22 Feb 18
HEPLISAV-B is the First and Only Two-Dose Vaccine in the U.S. for Hepatitis B Prevention in Adults
12:00am
8-K
4ajwxa
20 Feb 18
Dynavax Secures $175 Million inNon-Dilutive Debt Financing
12:00am
8-K
vb3 tpo35yet
9 Jan 18
Dynavax Announces HEPLISAV-B™ is Now Available in the United States
12:00am
8-K
n01xepp rb
5 Jan 18
Results of Operations and Financial Condition
12:00am
8-K
0uk6zxst3go2a8q8m
30 Nov 17
Departure of Directors or Certain Officers
12:00am
8-K
po7ktlflgiaqpv5 2c
14 Nov 17
Entry into a Material Definitive Agreement
12:00am
8-K
830hxn
3 Nov 17
Dynavax Reports Third Quarter 2017 Financial Results
12:00am
8-K
q91ux
1 Sep 17
Other Events
12:00am
8-K
81crmf1w
10 Aug 17
Entry into a Material Definitive Agreement
12:00am
8-K
el8po1yk k4a7b113sn
7 Aug 17
Dynavax Provides U.S. Regulatory Update onHEPLISAV-B™ Following FDA Advisory Committee Meeting
12:00am
8-K
47prsbb l8
2 Aug 17
Dynavax Reports Second Quarter 2017 Financial Results
12:00am
8-K
l4mxe abyo9zoox1ly
31 Jul 17
Dynavax Announces FDA Advisory Committee
12:00am